当社グループは 3,000 以上の世界的なカンファレンスシリーズ 米国、ヨーロッパ、世界中で毎年イベントが開催されます。 1,000 のより科学的な学会からの支援を受けたアジア および 700 以上の オープン アクセスを発行ジャーナルには 50,000 人以上の著名人が掲載されており、科学者が編集委員として名高い
。オープンアクセスジャーナルはより多くの読者と引用を獲得
700 ジャーナル と 15,000,000 人の読者 各ジャーナルは 25,000 人以上の読者を獲得
Li Zhang, Na Li, Li Song, Wanqi Zheng, Yong Li Zhao and Zhengjuan Liu
The side effects of glucocorticoid-induced insulin resistance (IR) have drawn increasing attention, but the information is scarce regarding treatment of glucocorticoid-induced insulin resistance in children. The study was conducted in children who received prolonged high-dose glucocorticoid for refractory nephrotic syndrome. The Body Mass Index (BMI) was monitored and metabolic parameters were determined. Homeostatic model assessment for insulin resistance index (HOMA-IR) was used for assessing glucocorticoid-induced IR. There were 41 obese children with HOMA-IR>3.5. The HOMA-IR showed a positive correlation with prednisone dosage, LDL-C, age and BMI (P<0.01), respectively. Multiple linear regression analysis showed that prednisone dosage, LDL-C, age and BMI correlated independently with HOMA-IR (P<0.05). Twenty-one children received metformin therapy as treated group and 20 patients received placebo as control group. After 3 months of treatment, the BMI and IR were significantly improved and the BMI and HOMA-IR were also significantly reduced compared to the control group. No significant toxicity from metformin was seen. Metformin is safe and effective for treatment of glucocorticoid-induced obesity and IR.